The device is designed to treat patients with AV block, a condition in which electrical signals between chambers of the heart are impaired.
Atrioventricular synchrony means the device detects cardiac movement so it can adjust its pacing in the ventricle to coordinate with the atrium.
Use of the Micra has shown a 63 percent decrease in major complications compared to traditional pacemakers, according to Larry Chinitz, MD, director of NYU Langone’s heart rhythm center.
Read the full news release here.
More articles on supply chain:
5 predictions for the medical device industry in 2020
EPA backs down on ethylene oxide queries after FDA marks turf
ResMed to pay US $37.5M to settle kickback allegations
